Biomarin Pharmaceutical Stock News

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lifted by Oppenheimer from $84.00 to $95.00 in a research report report published on Monday, The Fly reports. The firm currently has a market perform rating on the biotechnology companys stock. Oppenheimer also issued estimates for BioMarin Pharmaceuticals Q4 2021 earnings at ($0.10) EPS, Q1 2022 earnings at []

If history is any guide, there may be good fortune ahead for Full story available on Benzinga.com

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / November 25, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn''t require that you serve as a lead plaintiff. A lead plaintiff ..

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Investment analysts at Wedbush raised their Q4 2021 earnings per share estimates for shares of BioMarin Pharmaceutical in a research note issued on Sunday, November 21st. Wedbush analyst L. Moussatos now expects that the biotechnology company will earn ($0.02) per share for the quarter, up from their prior estimate of []

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price objective increased by JPMorgan Chase & Co. from $129.00 to $135.00 in a report issued on Monday morning, The Fly reports. They currently have an overweight rating on the biotechnology company’s stock. Several other analysts have also recently issued reports on the stock. Piper Sandler upped their target price […]

Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by investment analysts at Guggenheim from $103.00 to $120.00 in a research note issued to investors on Monday, The Fly reports. The brokerage presently has a buy rating on the biotechnology companys stock. Guggenheims price target indicates a potential upside of 33.65% from the stocks current price. []

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock analysts at Wedbush raised their FY2022 earnings per share estimates for BioMarin Pharmaceutical in a report released on Sunday, November 21st. Wedbush analyst L. Moussatos now forecasts that the biotechnology company will post earnings per share of $1.99 for the year, up from their previous forecast of $1.84. Wedbush []

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / November 23, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn''t require that you serve as a lead plaintiff. A lead plaintiff ..

Analysts expect BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to announce ($0.01) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Nine analysts have provided estimates for BioMarin Pharmaceuticals earnings, with estimates ranging from ($0.22) to $0.12. BioMarin Pharmaceutical posted earnings of $0.21 per share in the same quarter last year, which suggests a negative []

Data Bridge Market research released a new market study on Advanced therapy medicinal products with 100+ market data Tables, Pie Chart, Graphs & Figures spread through Pages and easy to understand detailed analysis In Advanced therapy medicinal products research

BioMarin Pharmaceutical (NASDAQ:BMRN) had its target price hoisted by SVB Leerink from $112.00 to $115.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have an outperform rating on the biotechnology companys stock. Several other analysts also recently issued reports on the company. Credit Suisse Group dropped their price target []

LOS ANGELES--(BUSINESS WIRE)---- $BMRN #BMRN--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc.